Literature DB >> 21959531

Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Gonca Tamer1, Ayşegül Telci, Meral Mert, Ayse Kubat Uzum, Ferihan Aral, Refik Tanakol, Sema Yarman, Harika Boztepe, Nese Colak, Faruk Alagöl.   

Abstract

One form of prolactin (PRL) is macroprolactin with high molecular mass. Many macroprolactinemic patients have no pituitary adenomas and no clinical symptoms of hyperprolactinemia, it is controversial whether macroprolactinemia is a benign condition that does not need further investigation and treatment. In this study, we aimed to compare macroprolactinemic patients (group I) with the true hyperprolactinemic patients (group II) for the presence of pituitary adenoma. We investigated 161 patients with hyperprolactinemia, whose magnetic resonance imaging records of the pituitary were taken. All patients were questioned for irregular menses, infertility and examined for galactorrhea. Patients were screened for macroprolactinemia by polyethylene glycol precipitation, and a recovery of ≤40% and normal monomeric PRL level was taken as an indication of significant macroprolactinemia. Of 161 patients with hyperprolactinemia, 60 (37.26%) had macroprolactinemia. PRL levels of group II were lower than those of group I (P = 0.011), although monomeric PRL levels of group II were higher than those of group I (P = 0.0005). Of 60 macroprolactinemic patients, 16 (26.7%) had pituitary adenomas. The prevalence of pituitary adenomas was lower in group I, compared with group II (P = 0.0005). No significant differences were found between the prevalences of irregular menses and infertility of group I and II (P = 0.084, P = 0.361). Prevalence of galactorrhea in group I was lower than that in group II (P = 0.048). Prevalence of pituitary adenomas in macroprolactinemic patients is lower compared with the true hyperprolactinemic patients, but may be higher than that found in other recent studies and in the general population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959531     DOI: 10.1007/s12020-011-9536-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  The macroprolactin problem.

Authors:  Janet A Schlechte
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

2.  Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays.

Authors:  Thomas P Smith; Abdulwahab M Suliman; Michael N Fahie-Wilson; T Joseph McKenna
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

3.  The impact on clinical practice of routine screening for macroprolactin.

Authors:  J Gibney; T P Smith; T J McKenna
Journal:  J Clin Endocrinol Metab       Date:  2005-04-05       Impact factor: 5.958

4.  Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients.

Authors:  Alfredo Leaños-Miranda; Guadalupe Cárdenas-Mondragón; Roxana Rivera-Leaños; Alfredo Ulloa-Aguirre; Vincent Goffin
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

5.  Characterization of "big big prolactin" in serum and tumor extract in patients with PRL-secreting tumor.

Authors:  S Ohnami; S Eto; S Ohnami; T Soejima; H Nakata
Journal:  Endocrinol Jpn       Date:  1987-06

6.  Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.

Authors:  H Leslie; C H Courtney; P M Bell; D R Hadden; D R McCance; P K Ellis; B Sheridan; A B Atkinson
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

7.  Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.

Authors:  Jae Won Hong; Mi Kyung Lee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2009-11-14       Impact factor: 3.633

8.  Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; F Dal Bosco
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

9.  Screening for macroprolactinaemia and pituitary imaging studies.

Authors:  Omar M Hauache; Antonio J Rocha; Antonio C M Maia; Rui M B Maciel; José Gilberto H Vieira
Journal:  Clin Endocrinol (Oxf)       Date:  2002-09       Impact factor: 3.478

10.  Should macroprolactin be measured in all hyperprolactinaemic sera?

Authors:  T Joseph McKenna
Journal:  Clin Endocrinol (Oxf)       Date:  2009-03-06       Impact factor: 3.478

View more
  8 in total

1.  Editorial: is macroprolactinemia just a diagnostic pitfall?

Authors:  Marcello D Bronstein
Journal:  Endocrine       Date:  2012-04       Impact factor: 3.633

2.  Clinical and radiological findings in macroprolactinemia.

Authors:  Serhat Isik; Dilek Berker; Yasemin Ates Tutuncu; Ufuk Ozuguz; Ferhat Gokay; Gonul Erden; Hatice Nursun Ozcan; Ferit Kerim Kucukler; Yusuf Aydin; Serdar Guler
Journal:  Endocrine       Date:  2011-12-21       Impact factor: 3.633

3.  Macroprolactinemia in hyperprolactinemic infertile women.

Authors:  Krithika Thirunavakkarasu; Pinaki Dutta; Subbiah Sridhar; Lakhbir Dhaliwal; G R V Prashad; Shalini Gainder; Naresh Sachdeva; Anil Bhansali
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

Review 4.  Concomitant myasthenia gravis and macroprolactinoma: the immunomodulatory role of prolactin and its potential therapeutic use.

Authors:  S M Harris; H M C Leong; R Chowdhury; C Ellis; John Brennan; I N Scobie
Journal:  Endocrine       Date:  2013-06-08       Impact factor: 3.633

5.  Male prolactinomas presenting with normal testosterone levels.

Authors:  Ilan Shimon; Carlos Benbassat
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 6.  Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis.

Authors:  Noor Azlin Azraini Che Soh; Najib Majdi Yaacob; Julia Omar; Aniza Mohammed Jelani; Noorazliyana Shafii; Tuan Salwani Tuan Ismail; Wan Norlina Wan Azman; Anis Kausar Ghazali
Journal:  Int J Environ Res Public Health       Date:  2020-11-06       Impact factor: 3.390

7.  Macroprolactinemia in a patient with invasive macroprolactinoma: a case report and minireview.

Authors:  Atanaska Elenkova; Zdravka Abadzhieva; Nikolai Genov; Vladimir Vasilev; Georgi Kirilov; Sabina Zacharieva
Journal:  Case Rep Endocrinol       Date:  2013-01-15

Review 8.  Macroprolactinemia: new insights in hyperprolactinemia.

Authors:  Miro Kasum; Slavko Oreskovic; Ivana Zec; Davor Jezek; Vlatka Tomic; Vesna Gall; Goran Adzic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.